The pharmaceutical contract packaging market size is expected to increase from USD 20.16 billion in 2025 to USD 20.82 billion in 2026 and reach USD 31.88 billion by 2031, growing at a CAGR of 8.89% over 2026-2031. This report is Segmented by Service Type (Primary, Secondary, Tertiary), Packaging Format (Bottles, Vials and Ampoules, and More), Drug Formulation (Solid Dosage, and More), End-User (Big Pharma, Generics/Biosimilar Companies, and More), and Geography. The Market Forecasts are Provided in Terms of Value (USD).
Other drivers and restraints analyzed in the detailed report include:
Tertiary solutions are forecast to outpace the rest of the sector at a 9.02% CAGR to 2031. Sponsors bundle case packing and pallet aggregation with secondary work to avoid data gaps between hierarchy levels. The pharmaceutical contract packaging market size for tertiary services therefore widens fastest in facilities that integrate automated pallet labelers with enterprise resource planning systems. Contractors that master this “last mile” deliverables save their clients validation cycles and reduce distribution errors, a premium many sponsors accept willingly.
Bottles held 32.94% of 2025 revenue, supporting high-volume generic therapies and pediatric liquids. However, patient preference and payer pressure move chronic biologics into at-home injection, spurring an 8.93% CAGR for pre-filled syringes and cartridges. Subcutaneous GLP-1 agonists and TNF-alpha inhibitors now launch primarily in auto-injectors, shifting packaging complexity from hospitals to contract fill-finish providers.
The pharmaceutical contract packaging market size tied to pre-filled platforms grows because each device combines sterile assembly, device calibration, and tamper evidence in one workflow. Contract packagers add isolators and single-use tubing to accelerate changeovers between biologics, maintaining sterility without lengthy cleaning. While glass vials remain for inpatient oncology and anesthesia, their relative share declines, reinforcing the structural pivot toward ready-to-use delivery systems.
Asia Pacific is the fastest-growing region at a 9.33% CAGR, anchored by India’s CRDMO surge from USD 7 billion in 2024 to a projected USD 14 billion in 2028. China remains the world’s second-largest pharma market, yet data-localization and U.S. Biosecure Act debates drive sponsors toward a China-plus-one model that positions India, South Korea, and Singapore as alternative hubs. Japan’s mature market emphasizes high-quality clinical-trial packaging, and Australia leverages its role as a rapid-start study locale, demanding flexible, label-intensive output.
Europe faces margin pressure from energy costs: German and Italian contractors saw 40-60% jumps in natural-gas expenditure from 2022-2024. Nevertheless, the bloc’s forthcoming recycled-content rules spur investment in sustainable carton lines. The United Kingdom specializes in early-phase trial kits, while Iberian plants win volume shifts owing to renewable-energy penetration. Middle East and Africa remain nascent but invest under healthcare diversification plans, and South America, led by Brazil, favors domestic blister lines to sidestep import tariffs.
Global Pharmaceutical Contract Packaging Market Trends and Insights
Serialization Mandates and Anti-Counterfeit Regulation Surge
National traceability rules have turned packaging into a compliance gate, forcing every carton to carry a unique 2D matrix and tamper-evident seal. In the United States, the Drug Supply Chain Security Act moved from lot-level to enhanced product-level verification in 2023, driving a new wave of outsourcing to partners already equipped with aggregation software.Europe’s Falsified Medicines Directive applies similar requirements, although Italy and Greece kept staggered deadlines through 2027, encouraging firms to rely on contract sites linked to the European hub. Turkey, Brazil, and South Korea each maintain distinct data templates, so contractors differentiate by offering validated, jurisdiction-specific line configurations. The result is a tangible uplift in demand for vision inspection, line-level printers, and middleware that smaller manufacturers cannot justify in-house. Outsourcing spreads those fixed costs across multiple clients, preserving capital for core R&D.Biologic and Specialty-Drug Boom Amplifying Sterile Packaging Demand
Biologic approvals rose again in 2024, and every new monoclonal antibody, cell therapy, or GLP-1 agonist requires aseptic fill-finish under cold-chain conditions. Sponsors favor pre-filled syringes that enable patient self-administration, cutting hospital visits and improving adherence. Because a single sterile line can cost USD 50-100 million, emerging biotech companies outsource to CDMOs that bundle modular cleanrooms with secondary labeling. Growth in this segment supports an 8.93% CAGR for pre-filled syringes, outpacing bottles and blisters. The Parenteral Drug Association’s revised guidance on single-use systems has lowered the barrier for contract sites to add capacity quickly.Evolving Global Track-and-Trace Standards Raise Compliance Costs
Every major market now demands serialization, but data schemas differ widely. Turkey’s system insists on real-time uploads, Brazil mandates its own aggregation hierarchy, and South Korea tightened reporting windows to 24 hours. Smaller contractors spend up to USD 1.5 million a year on software updates to keep pace, eroding margin. Multinational sponsors expect flawless compliance, and any mismatch can trigger recalls or shipment holds in China under 2024 law amendments. Until global harmonization takes hold, packagers must operate parallel IT stacks, limiting economies of scale.Other drivers and restraints analyzed in the detailed report include:
- CDMO One-Stop-Shop Preference
- Supply-Chain Near-Shoring by Big Pharma
- Poly-Material Sustainability Rules Squeeze Margin on Plastics
Segment Analysis
Secondary services accounted for 44.73% of the pharmaceutical contract packaging market in 2025 as carton serialization became unavoidable. Each carton now embeds a unique data matrix inspected at speeds above 200 units per minute, reinforcing demand for high-speed cameras and rejection systems. Primary activities, such as vial forming and bottle molding, remain largely in-house for manufacturers, yet contractors increasingly receive bulk containers for labeling and over-wrapping.Tertiary solutions are forecast to outpace the rest of the sector at a 9.02% CAGR to 2031. Sponsors bundle case packing and pallet aggregation with secondary work to avoid data gaps between hierarchy levels. The pharmaceutical contract packaging market size for tertiary services therefore widens fastest in facilities that integrate automated pallet labelers with enterprise resource planning systems. Contractors that master this “last mile” deliverables save their clients validation cycles and reduce distribution errors, a premium many sponsors accept willingly.
Bottles held 32.94% of 2025 revenue, supporting high-volume generic therapies and pediatric liquids. However, patient preference and payer pressure move chronic biologics into at-home injection, spurring an 8.93% CAGR for pre-filled syringes and cartridges. Subcutaneous GLP-1 agonists and TNF-alpha inhibitors now launch primarily in auto-injectors, shifting packaging complexity from hospitals to contract fill-finish providers.
The pharmaceutical contract packaging market size tied to pre-filled platforms grows because each device combines sterile assembly, device calibration, and tamper evidence in one workflow. Contract packagers add isolators and single-use tubing to accelerate changeovers between biologics, maintaining sterility without lengthy cleaning. While glass vials remain for inpatient oncology and anesthesia, their relative share declines, reinforcing the structural pivot toward ready-to-use delivery systems.
Complete Report Scope:
- By Service Type
- Primary
- Bottles
- Vials and Ampoules
- Blister Packs
- Secondary
- Cartons
- Labels and Inserts
- Tertiary
- Primary
- By Packaging Format
- Bottles
- Plastic Bottles
- Glass Bottles
- Vials and Ampoules
- Blister Packs
- Sachets and Stick Packs
- Pre-filled Syringes and Cartridges
- Bottles
- By Drug Formulation
- Solid Dosage
- Tablets
- Capsules
- Oral Liquids
- Injectable
- Small-volume Parenterals
- Large-volume Parenterals
- Solid Dosage
- By End-user
- Big Pharma (Revenue > USD 10 bn)
- Generics and Biosimilar Companies
- Emerging Biotech and Start-ups
- CRO and CDMO Partners
- Other End-users
- By Geography
- North America
- United States
- Canada
- Mexico
- South America
- Brazil
- Argentina
- Rest of South America
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Australia and New Zealand
- Rest of Asia-Pacific
- Middle East
- United Arab Emirates
- Saudi Arabia
- Turkey
- Rest of Middle East
- Africa
- South Africa
- Nigeria
- Egypt
- Rest of Africa
- North America
Geography Analysis
North America generated 35.84% of 2025 revenue, with the United States benefiting from industrial-policy tax credits and stringent FDA inspection readiness. Sponsors prize contractors that can host a pre-approval audit within weeks, so facilities in the Midwest and Northeast cluster near distribution corridors. Canada supplements capacity for bilingual labeling and Health Canada serialization, often absorbing U.S. overflow during launch spikes.Asia Pacific is the fastest-growing region at a 9.33% CAGR, anchored by India’s CRDMO surge from USD 7 billion in 2024 to a projected USD 14 billion in 2028. China remains the world’s second-largest pharma market, yet data-localization and U.S. Biosecure Act debates drive sponsors toward a China-plus-one model that positions India, South Korea, and Singapore as alternative hubs. Japan’s mature market emphasizes high-quality clinical-trial packaging, and Australia leverages its role as a rapid-start study locale, demanding flexible, label-intensive output.
Europe faces margin pressure from energy costs: German and Italian contractors saw 40-60% jumps in natural-gas expenditure from 2022-2024. Nevertheless, the bloc’s forthcoming recycled-content rules spur investment in sustainable carton lines. The United Kingdom specializes in early-phase trial kits, while Iberian plants win volume shifts owing to renewable-energy penetration. Middle East and Africa remain nascent but invest under healthcare diversification plans, and South America, led by Brazil, favors domestic blister lines to sidestep import tariffs.
List of Companies Covered in this Report:
- PCI Pharma Services
- Catalent Inc.
- Sharp Packaging Services
- Almac Group
- Wasdell Group
- Ropack Inc.
- Reed-Lane Inc.
- Jones Healthcare Group
- Recipharm AB
- Tjoapack Netherlands B.V.
- AmeriPac (Veritiv Corporation)
- Silgan Unicep
- Nelipak
- Aphena Pharma Solutions
- Central Pharma Contract Packing
- Quantrelle Packaging Solutions
- Variopack GmbH
- Sepha Ltd.
- Assemblies Unlimited
- DaklaPack Group
- Tripak Pharmaceuticals
- MPH Co-Packing
- Southwest Packaging
- MJS Packaging
- Jam Jams Group
- Asiapack (Elanders Group)
- Finishing Services
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 INTRODUCTION
4 MARKET LANDSCAPE
5 MARKET SIZE AND GROWTH FORECASTS (VALUE)
6 COMPETITIVE LANDSCAPE
7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- PCI Pharma Services
- Catalent Inc.
- Sharp Packaging Services
- Almac Group
- Wasdell Group
- Ropack Inc.
- Reed-Lane Inc.
- Jones Healthcare Group
- Recipharm AB
- Tjoapack Netherlands B.V.
- AmeriPac (Veritiv Corporation)
- Silgan Unicep
- Nelipak
- Aphena Pharma Solutions
- Central Pharma Contract Packing
- Quantrelle Packaging Solutions
- Variopack GmbH
- Sepha Ltd.
- Assemblies Unlimited
- DaklaPack Group
- Tripak Pharmaceuticals
- MPH Co-Packing
- Southwest Packaging
- MJS Packaging
- Jam Jams Group
- Asiapack (Elanders Group)
- Finishing Services
